Frequent Links
Edivoxetine
| File:Edivoxetine structure.png | |
| Systematic (IUPAC) name | |
|---|---|
| (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(tetrahydro-2H-pyran-4-yl)ethanol | |
| Clinical data | |
| Identifiers | |
|
1194508-25-2 1194374-05-4 (hydrochloride) | |
| None | |
| PubChem | CID 11186829 |
| ChemSpider | 9361913 |
| Chemical data | |
| Formula | C18H26FNO4 |
| 339.402 g/mol | |
| |
| |
Edivoxetine (INN; LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment.[1][2] It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.[1][3]
Effectiveness
In a study published in 2010, edivoxetine failed to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]
In a study published in 2011, using the Montgomery-Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]
Side effects
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]
The above mention studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]
See also
References
- ^ a b Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News (American Psychiatric Association) 47 (5): 1b-29. Retrieved 2012-04-27.
- ^ "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (PDF) (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
- ^ Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery 10 (11): 809–10. PMID 22037032. doi:10.1038/nrd3585.
- ^ a b c Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research 44 (6): 356–363. PMID 19909980. doi:10.1016/j.jpsychires.2009.09.013.
- ^ a b Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research 45 (6): 748–755. PMID 21511276. doi:10.1016/j.jpsychires.2011.03.014.
- ^ https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751